Search TLSIW
TriSalus Life Sciences, Inc.
Nasdaq, Nasdaq · CIK 1826667
Last close0.85
Daily change+0.01 (1.19%)
10 Years gain-70.76%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TLSIW · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
55.0Momentum
n/aAcceleration
n/aConfidence
64.0Annual Revenue4
Quarterly Revenue12
Annual CFO5
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality14.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet13.2 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 104.353%.
Key Metrics
Revenue Growth TTM42.02%OK
Revenue CAGR 3Y53.85%OK
Gross Margin85.04%OK
Operating Margin-80.24%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y104.35%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $45.15M | $38.19M | -$26.95M | -$18.01M | -$18.93M | 84.57% | -59.68% | -41.93% | n/a | 37.9M |
| 2025 FY Dec 31, 2024 | $29.43M | $25.33M | -$36.17M | -$40.84M | -$41.19M | 86.06% | -122.88% | -139.95% | n/a | 25.33M |
| 2024 FY Dec 31, 2023 | $18.51M | $15.91M | -$54.48M | -$50.58M | -$51.17M | 85.93% | -294.28% | -276.41% | n/a | 9.4M |
| 2023 FY Dec 31, 2022 | $12.40M | $10.14M | -$36.44M | -$32.31M | -$32.97M | 81.79% | -293.91% | -265.91% | n/a | 309,609 |
| 2022 FY Dec 31, 2021 | n/a | n/a | -$3.04M | -$1.74M | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $43.09M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-054275, 0001628280-25-052043 |
| Revenue Growth TTM | 42.02% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-054275, 0001628280-25-052043 |
| Revenue CAGR 3Y | 53.85% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-015163 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-015163 |
| Gross Profit CAGR 3Y | 55.58% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-015163 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-054275, 0001628280-25-052043 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 85.04% | Gross Profit / Revenue | OK | 0001628280-26-054275, 0001628280-25-052043 |
| Operating Margin | -80.24% | Operating Income / Revenue | OK | 0001628280-26-054275, 0001628280-25-052043 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-054275 |
| Current Ratio | 5.35x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.4x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-054275 |
| Revenue per Diluted Share | $0.74 | Revenue / Diluted Shares | OK | 0001628280-26-054275, 0001628280-25-052043 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |